Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1399-1406

  Radosa, Marc P ^a   Häfner, Norman ^a   Camara, Oumar ^a   Diebolder, Herbert ^a   Mothes, Anke ^a   Winzer, Harald ^a   Jansen, Lars ^a   Dürst, Matthias ^a   Runnebaum, Ingo B ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

BRCA1; BRCAness; Gene expression regulation; Prognostic marker; Sporadic epithelial ovarian cancer

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYSTADENOCARCINOMA; DNA METHYLATION; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SURVIVAL TIME; TRANSCRIPTION REGULATION; TREATMENT DURATION; ADENOCARCINOMA; GERMANY; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CARBOPLATIN; FEMALE; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PHENOTYPE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84857475389     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318227c990     Document Type: Article

References (29)

1. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807-2816. (Pubitemid 41798292)
2. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle. 2008;7:1353-1359. (Pubitemid 351872573)
3. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285-1291. (Pubitemid 36606348)
4. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness"syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530-5536.
5. Thrall M, Gallion HH, Kryscio R, et al. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2006;16:166-171.
6. Clark-Knowles KV, O'Brien AM, Weberpals JI. BRCA1 as a therapeutic target in sporadic epithelial ovarian cancer. J Oncol. 2010;2010:891059.
7. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4:814-819. (Pubitemid 39331153)
8. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555-3561.
9. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-1244.
10. Wilson CA, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999;21:236-240. (Pubitemid 29070375)
11. Al-Mulla F, Abdulrahman M, Varadharaj G, et al. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem. 2005;53:621-629. (Pubitemid 40593975)
12. Häfner N, Gajda M, Altgassen C, et al. HPV16-E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse-transcription PCR. Int J Cancer. 2007;120:1842-1846. (Pubitemid 46418358)
13. Häfner N, Diebolder H, Jansen L, et al. Hypermethylated DAPK in serum of women with uterine leiomyoma is a biomarker not restricted to cancer. Gynecol Oncol. 2011;121:224-229.
14. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564-569. (Pubitemid 30212318)
15. Wilcox CB, Baysal BE, Gallion HH, et al. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005;159:114-122. (Pubitemid 40719379)
16. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148-1159.
17. Barton CA, Clark SJ, Hacker NF, et al. Epigenetic markers of ovarian cancer. Adv Exp Med Biol. 2008;622:35-51.
18. Tangjitgamol S, Hanprasertpong J, Manusirivithaya S, et al. Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes. Acta Obstet Gynecol Scand. 2010;89:182-189.
19. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997;336:1125-1130.
20. Ibanez de Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64:6476-6481. (Pubitemid 39297903)
21. Couzin J. Choices - and uncertainties - for women with BRCA mutations. Science. 2003;302:592.
22. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265. (Pubitemid 30246777)
23. Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol. 2002;14:19-26. (Pubitemid 34177903)
24. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16:4702-4710.
25. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010;16:6159-6168.
26. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010;16:2344-2351.
27. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245-251.
28. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512-2519.
29. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108:3406-3411.